PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer

Summary

The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy

Conditions

• Endometrial Cancer Stage III
• Endometrial Cancer Stage IV
• Endometrial Cancer Recurrent

Interventions

DRUG

Hormonal Antineoplastics

Hormonal therapy used for treatment in endometrial cancer patients

Sponsors & Collaborators

• Haukeland University Hospital

  collaborator OTHER

• Maastricht University Medical Center

  collaborator OTHER

• Brno University Hospital

  collaborator OTHER

• Holycross Cancer Center Kielce

  collaborator UNKNOWN

• Medical University of Lublin

  collaborator OTHER

• Hospital del Mar

  collaborator OTHER

• Hospital Vall d'Hebron

  collaborator OTHER

• Royal Cornwall Hospitals Trust

  collaborator OTHER

• Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  collaborator OTHER

• The Netherlands Cancer Institute

  collaborator OTHER

• Canisius-Wilhelmina Hospital

  collaborator OTHER

• Catharina Ziekenhuis Eindhoven

  collaborator OTHER

• Erasmus Medical Center

  collaborator OTHER

• Leiden University Medical Center

  collaborator OTHER

• Radboud University Medical Center

  lead OTHER

Principal Investigators

• Hanny Pijnenborg, MD PhD · Radboud University Medical Center

• Roy Lalisang, MD PhD prof · Maastricht University Medical Center

• Andrea Romano, MD PhD · Maastricht University

• Willem Jan Van Weelden, MD · Radboud University Medical Center

Eligibility

Min Age

18 Years

Max Age

110 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-10-15

Primary Completion

2026-10-15

Completion

2027-09-01

Countries

• Netherlands

Study Locations